Samsung BioLogics Co Ltd
207940
Company Profile
Business description
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2024, Samsung Biologics had a total production capacity of 754,000 liters, one of the largest in the world. Its CDMO services account for 66.2% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Contact
125, Cheomdan-daero
Yeonsu-gu
Incheon
KORSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,011
Stocks News & Analysis
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.10 | 1.60 | 0.02% |
| CAC 40 | 7,698.92 | 20.79 | -0.27% |
| DAX 40 | 23,770.33 | 175.53 | 0.74% |
| Dow JONES (US) | 45,621.29 | 350.06 | 0.77% |
| FTSE 100 | 9,216.87 | 38.88 | 0.42% |
| HKSE | 25,212.64 | 154.13 | 0.62% |
| NASDAQ | 21,707.69 | 209.97 | 0.98% |
| Nikkei 225 | 42,890.85 | 310.58 | 0.73% |
| NZX 50 Index | 13,176.70 | 43.50 | 0.33% |
| S&P 500 | 6,502.08 | 53.82 | 0.83% |
| S&P/ASX 200 | 8,862.30 | 0.30 | -0.00% |
| SSE Composite Index | 3,773.04 | 7.16 | 0.19% |